Boston Scientific Corporation
Boston Scientific Resumes AVANT GUARD Clinical Trial for New Patient Population
Summary
On November 7, 2024, Boston Scientific Corporation announced the resumption of the AVANT GUARD clinical trial for a new population of drug-naïve patients with persistent atrial fibrillation. This decision follows an assessment of observations within the trial and in conjunction with the study's data monitoring committee.
Profitelligence Alerts
Get alerts for BSX
Be first to know when Boston Scientific Corporation files with the SEC.
Filing Categories
Advertisement
About Boston Scientific Corporation
Boston Scientific Corporation, a leading global medical device company, is renowned for developing and supplying innovative health solutions. Its primary function is to design, manufacture, and market medical devices used in interventional medical specialties such as cardiology, peripheral interventions, cardiac rhythm management, endoscopy, urology, and neuromodulation. The company's product offerings significantly impact sectors like health care, particularly those focusing on minimally invasive treatments. Boston Scientific's products help improve the quality of patient care and reduce the need for major surgery, thus playing a crucial role in modern healthcare systems. Their devices contribute to procedures that are less invasive, more effective, and often more economic, supporting better patient outcomes and quicker recovery times. Founded in 1979 and headquartered in Marlborough, Massachusetts, Boston Scientific provides its products to healthcare providers and institutions worldwide. In the financial markets, Boston Scientific Corporation holds significant influence as a major player in the healthcare industry, contributing to advancements in medical technology and shaping the future of patient care through research and development. Its presence underscores the importance of innovation in medical devices and its role in enhancing healthcare delivery.
Official SEC Documents
Advertisement